If you or a loved one has taken Ozempic and developed severe stomach issues like gastroparesis, you're likely seeking clear answers. This guide reviews reported cases in Ohio, FDA safety communications, and what the science says about the link between GLP-1 drugs and delayed gastric emptying. Building on decades of pharmaceutical safety monitoring, we provide a factual overview of symptoms, diagnosis, and next steps.
Gastroparesis is a disorder characterized by delayed gastric emptying in the absence of mechanical obstruction, leading to symptoms such as nausea, vomiting, early satiety, bloating, and abdominal pain. Clinical diagnosis typically involves gastric emptying scintigraphy, which measures the rate at which food leaves the stomach. The condition can significantly impair quality of life and may require dietary modifications, medications, or more invasive interventions. Ozempic (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist approved for the treatment of type 2 diabetes mellitus. Its pharmacology involves slowing gastric emptying, which contributes to its glucose-lowering effects but also underlies many of its gastrointestinal adverse effects. In placebo-controlled trials, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic than placebo: 32.7% with Ozempic 0.5 mg, 36.4% with Ozempic 1 mg, and 15.3% with placebo (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The majority of reports of nausea, vomiting, and/or diarrhea occurred during dose escalation (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). More patients receiving Ozempic 0.5 mg (3.1%) and Ozempic 1 mg (3.8%) discontinued treatment due to gastrointestinal adverse reactions than patients receiving placebo (0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). In a trial with Ozempic 1 mg and 2 mg, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic 2 mg (34.0%) versus Ozempic 1 mg (30.8%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Specific adverse reactions reported in ≥5% of Ozempic-treated patients with type 2 diabetes mellitus include nausea (15.8% with 0.5 mg, 20.3% with 1 mg), vomiting (5.0% with 0.5 mg, 9.2% with 1 mg), diarrhea (8.5% with 0.5 mg, 8.8% with 1 mg), abdominal pain (7.3% with 0.5 mg, 5.7% with 1 mg), and constipation (5.0% with 0.5 mg, 3.1% with 1 mg) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). These data highlight the frequency of gastrointestinal symptoms that can overlap with or mimic gastroparesis.
The mechanistic pathway linking Ozempic to gastroparesis involves its action as a GLP-1 receptor agonist, which delays gastric emptying. While this effect is intended to improve glycemic control, it can become pathological in some patients, leading to clinically significant gastroparesis. The timeline between exposure and documented harm can vary; symptoms often emerge during dose escalation, but persistent gastroparesis may develop after prolonged use. The label does not explicitly list gastroparesis as a warning, but the high rates of nausea, vomiting, and abdominal pain suggest a potential for this condition. Regarding the adequacy of warnings, the Ozempic label includes a section on hypersensitivity reactions, such as anaphylaxis and angioedema, but does not specifically warn about gastroparesis (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). This omission may be relevant for patients who develop severe gastrointestinal symptoms that persist beyond dose escalation.
For affected patients in Ohio, attorney-related considerations include the statute of limitations for product liability claims. In Ohio, the statute of limitations for personal injury claims is generally two years from the date of injury or from when the injury was discovered or should have been discovered. For claims involving defective drugs, the timeline may be influenced by when the patient became aware of the link between Ozempic and their gastroparesis. Given that gastrointestinal adverse reactions are common and often attributed to the drug, patients who experience persistent symptoms should seek medical evaluation and legal counsel promptly. The timeline between exposure and documented harm is critical for legal claims. Patients who develop gastroparesis after starting Ozempic should document the onset of symptoms, the duration of use, and any medical diagnoses. The label data indicate that gastrointestinal adverse reactions are most frequent during dose escalation, but some patients may experience delayed onset. The lack of a specific warning about gastroparesis may affect the adequacy of warnings, potentially supporting claims of failure to warn. In summary, Ozempic use is associated with a high incidence of gastrointestinal adverse reactions, including nausea, vomiting, and abdominal pain, which can be consistent with gastroparesis. The drug's mechanism of delaying gastric emptying provides a plausible link to this condition. Patients in Ohio who develop gastroparesis after using Ozempic should be aware of the two-year statute of limitations and consult an attorney to evaluate their case. The adequacy of warnings remains a key issue, as the label does not specifically address gastroparesis.
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
In Ohio, the statute of limitations for personal injury claims, including product liability for defective drugs, is generally two years from the date of injury or from when the injury was discovered or should have been discovered. For Ozempic-related gastroparesis, this means the clock typically starts when you become aware of the link between your use of Ozempic and your gastroparesis diagnosis. It is crucial to consult an attorney promptly to ensure your claim is filed within this timeframe.
No, the Ozempic label does not explicitly list gastroparesis as a warning. While it includes a section on hypersensitivity reactions such as anaphylaxis and angioedema, it does not specifically warn about gastroparesis (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). This omission may be relevant for patients who develop severe gastrointestinal symptoms that persist beyond dose escalation, potentially supporting claims of failure to warn.
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.
Request archival records or inquire about member-exclusive transition and benefit programs.
Individuals with documented archive exposure and a related diagnosis may request an independent, no-cost eligibility review.